Two top Asia-focused investment trusts
Pacific Assets and Scottish Oriental are both trusts that focus on high-quality companies controlled by trustworthy families or founders

Until FSSA split from Stewart Investors nearly ten years ago, Pacific Assets Trust (LSE: PAC) and Scottish Oriental Smaller Companies Trust (LSE: SST) were managed under the same roof, with the former investing in larger companies in Asia, excluding Japan, and the latter in smaller companies. A decade later, it’s as if they never parted company.
The performance of SST, with £500 million of net assets, is ahead of Pacific Assets, with £410 million – 65% versus 52% over five years, 41% versus 15% over three and 15% versus 10% over one. That’s thanks to the outperformance of smaller companies in Asia, which has been unusual in a global context. Relative to their own benchmark indices, SST is well ahead over one and three years and slightly ahead over five, while Pacific Assets is well ahead over five and three years but 10% behind over one. Both trade on a mid-teens discount to net asset value (NAV).
The weak recent performance of Pacific Assets is attributable to its low exposure to China, which accounts for 10% of the portfolio against 41% for India. “The vast majority of the Chinese market is state-owned or controlled,” says manager Douglas Ledingham of Stewart Investors. “We don’t want to hand your money to the Chinese Communist Party.”
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE

Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Stewart Investors favours family-controlled companies (57% of the portfolio) or ones controlled by entrepreneurs (28%), though Ledingham adds that there are some “very questionable” families in Asia. “We see only 3% of the largest 100 Chinese companies as investible against 27% for India.” Quality, sustainability and reliable people are the key characteristics he looks for.
The investment approach of Sree Agarwal of FSSA, the manager of SST, is similar but with more focus on reasonably priced long-term growth. SST is looking for “small caps which have the potential to be the large caps of the future”.
Trimming India
Pacific Assets puts more emphasis on long-term holdings with an average holding period of ten years, while SST appears more pragmatic. This showed last year, when SST’s exposure to India was significantly reduced in favour of China, Hong Kong and Taiwan. “We have been trimming some of our Indian companies on valuation grounds in favour of very high-quality names in China and Southeast Asian markets, which are trading at rarely seen valuations,” says Agarwal. The trust still has 34% of the portfolio in India but 25% is now in China and another 11% in Hong Kong and Taiwan.
For example, Agarwal has bought into DPC Dash, now the largest holding at 6.9% of SST. It holds the Domino’s Pizza franchise in China, where it is gaining momentum. China has just one-third the number of pizza stores per capita compared to Japan and South Korea, he says. “We expect it to grow at a mid-teens rate, while market leader Pizza Hut has been losing market share." The founders of DPC Dash bought the franchise, which had 18 stores, in 2010. By the end of 2024 it had more than 1,000 stores in 39 cities, yet has the potential to become several times its current size.
Both managers remain long- term bullish on Indian equities, despite their strong performance and high valuations. “The median age of Indians is only 35,” says Ledingham, “and manufacturing wages are just a quarter of those in China. As a result, a quarter of iPhones are now made in India.”
Pacific Assets’ holdings have little overlap with the larger Asia and emerging markets trusts and funds. SST is one of three Asian small cap specialists but there are no trusts covering small caps across all emerging markets. Both look attractive, but SST’s shrewd navigation of the return to favour of Chinese equities, while most commentators have remained sceptical surely gives it the edge.
This article was first published in MoneyWeek's magazine. Enjoy exclusive early access to news, opinion and analysis from our team of financial experts with a MoneyWeek subscription.
Sign up for MoneyWeek's newsletters
Get the latest financial news, insights and expert analysis from our award-winning MoneyWeek team, to help you understand what really matters when it comes to your finances.

Max has an Economics degree from the University of Cambridge and is a chartered accountant. He worked at Investec Asset Management for 12 years, managing multi-asset funds investing in internally and externally managed funds, including investment trusts. This included a fund of investment trusts which grew to £120m+. Max has managed ten investment trusts (winning many awards) and sat on the boards of three trusts – two directorships are still active.
After 39 years in financial services, including 30 as a professional fund manager, Max took semi-retirement in 2017. Max has been a MoneyWeek columnist since 2016 writing about investment funds and more generally on markets online, plus occasional opinion pieces. He also writes for the Investment Trust Handbook each year and has contributed to The Daily Telegraph and other publications. See here for details of current investments held by Max.
-
Anne Wojcicki: the daring 23andMe CEO who reached too far
Profile Anne Wojcicki dreamed of a revolution in personal genomics and medicine and set up 23andMe in 2006. Its collapse into bankruptcy provides a cautionary tale
By Jane Lewis Published
-
The star small and mid-cap stocks income investors have overlooked
Opinion Thomas Moore, senior investment director, Aberdeen, highlights three company stocks as he shares where he would put his money
By Thomas Moore Published
-
Cash in on the biotech sector with specialist trust BioPharma
Opinion BioPharma has an attractive niche in lending to asset-rich biotechnology companies
By Rupert Hargreaves Published
-
How to generate income with fixed-interest investments
Public debt is overvalued, but other fixed-interest investments now look like a bargain, says Max King
By Max King Published
-
Boaz Weinstein: the hedge fund ‘vulture’ swooping on the City
Profile Boaz Weinstein’s campaign to take over and transform “the Miserable Seven” London-based investment trusts has been routed – for now. The fight isn’t over yet
By Jane Lewis Published
-
Are UK Reits the most unloved asset?
Recent updates from UK Reits are looking more positive, but the market remains entirely unimpressed
By Cris Sholto Heaton Published
-
Majedie sees an impressive turnaround under Marylebone
Majedie Investments, a once-ailing trust has seen its discount shrink to almost nothing under its new manager, Marylebone Partners
By Max King Published
-
Should you invest in emerging markets?
Emerging markets offer strong, long-term growth and excellent value, says Rupert Hargreaves
By Rupert Hargreaves Published
-
Should you put your trust in investment trusts?
British investors have steered clear of investment trusts in recent years. They are missing a trick, says Max King
By Max King Published
-
The best ways to invest in Vietnam – Asia’s communist dynamo
Vietnam has long been one of our favourite markets. The prognosis remains auspicious, says Alex Rankine.
By Alex Rankine Published